Algeta ASA : to host Capital Markets Days

Not intended for US media
  
Oslo, Norway, 18 November 2013 - Algeta ASA (OSE: ALGETA), a company focused on the development of novel targeted cancer therapeutics, will host Capital Markets Days this week in Oslo, London and New York.  

Presentations by Algeta's Executive Management and invited guest speakers will cover topics including alpha-pharmaceutical production, a commercial update and the current life-cycle management clinical trial plan for Xofigo^® (radium Ra 223 dichloride) as well as Algeta's pipeline of Targeted Thorium Conjugates.

Event summaries and guest speaker details are provided below.

Oslo, 18 November 10:00am-2:00pm (CET)
KS-Agenda Møtesenter, Haakon VII's gate 9

• Dr Dag Clement Johannessen, Consultant Oncologist, Department of Oncology, University Hospital of Oslo, Norway 

• Dr Sten Nilsson, Professor of Oncology, Karolinska Institutet and University Hospital, Stockholm, Sweden 

London, 19 November 10:00am-2:00pm (GMT)
Holborn Bars 2^nd Floor, 138-142 Holborn

• Dr E. David Crawford, Professor of Surgery (Urology) & Radiation Oncology, Head Urologic Oncology, University of Colorado, Denver, USA  

• Dr Sten Nilsson, Professor of Oncology, Karolinska Institutet and University Hospital, Stockholm, Sweden 

New York, 21 November 12.30pm-4:30pm (EDT)
Parker Meridien, 118 West 57^th Street

• Dr Dan George, Director, GU Oncology, Duke Cancer Institute, Duke University Medical Center, Durham, North Carolina, USA 

• Dr Neal D. Shore, Director, CPI, Carolina Urologic Research Center, Atlantic Urology Clinics, Myrtle Beach, South Carolina, USA 

The event in New York will be webcast via www.algeta.com:
http://www.algeta.com/, where presentations will also be made available.

About Xofigo^® (Radium Ra 223 Dichloride)

Xofigo is approved in Europe for the treatment of adults with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases. Xofigo is an alpha particle-emitting pharmaceutical. Its active moiety mimics calcium and selectively targets bone, specifically areas of bone metastases, by forming complexes with the bone mineral hydroxyapatite. The high linear energy transfer of alpha emitters (80 keV/micrometer) leads to a high frequency of double-strand DNA breaks in adjacent tumour cells, resulting in a potent cytotoxic effect. Additional effects on the tumour microenvironment including osteoblasts and osteoclasts also contribute to the in vivo efficacy. The alpha particle range from radium-223 is less than 100 micrometers (less than 10 cell diameters) which minimises damage to the surrounding normal tissue.

Xofigo is also approved in the US for the treatment of castration-resistant prostate cancer, symptomatic bone metastases and no known visceral disease.

In September 2009, Algeta signed an agreement with Bayer for the development and commercialization of radium-223. Under the terms of the agreement, Bayer will develop, apply for health authority approvals worldwide and commercialize Xofigo globally. Algeta is eligible for royalties and milestones based on Bayer's sales of Xofigo outside the US, and Algeta US, LLC is co-promoting Xofigo with Bayer in the US.

Xofigo^® is a registered trademark of Bayer AG

###

For further information, please contact:

About Algeta
  
Algeta is a company focused on developing, manufacturing and marketing novel targeted therapies for patients with cancer. The Company is headquartered in Oslo, Norway, and has a US subsidiary, Algeta US, LLC, based in Cambridge, MA performing commercial marketing operations in the US. Algeta is listed on the Oslo Stock Exchange (Ticker: ALGETA). For more information please visit www.algeta.com:
http://www.algeta.com/.